Views

Abstract: 3227

PDF (English): 1628

Cited-by

1. Movahedan M, Ellis UM, Barry AR. Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients with Heterozygous Familial Hypercholesterolemia: A Meta-analysis. American Journal of Cardiovascular Drugs. 2025;25(1):47. doi: 10.1007/s40256-024-00682-0
2. Singh R, Chandi SK, Sran S, Aulakh SK, Nijjar GS, Singh K, et al. Emerging Therapeutic Strategies in Cardiovascular Diseases. Cureus. 2024;. doi: 10.7759/cureus.64388
3. Qiao W, Feng Y, Wen Z, Dou L, Li Y. Effect of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Lipoprotein(a) Levels: An Umbrella Review of Meta-analyses of Randomized Controlled Trials. Drugs. 2026;86(2):217. doi: 10.1007/s40265-025-02274-x
4. Preta G. Development of New Genome Editing Tools for the Treatment of Hyperlipidemia. Cells. 2023;12(20):2466. doi: 10.3390/cells12202466
5. Mijnster RJ, Mulder JW, Galema-Boers AM, Mattace-Raso F, Muller M, Lafeber M, et al. Efficacy and safety of PCSK9 monoclonal antibodies in older patients: A real-world registry. Atherosclerosis. 2025;408:120229. doi: 10.1016/j.atherosclerosis.2025.120229
6. Alanazi M, Al‐kuraishy HM, Hussain NR, Waheed HJ, Al‐Gareeb AI, Albuhadily AK, et al. Targeting of PCSK9 in the Management of Alzheimer's Disease: Expanding the New Potential Key Player. Drug Development Research. 2026;87(2). doi: 10.1002/ddr.70231
7. Xiao G, Gao S, Xie Y, Wang Z, Shu M. Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis. Medicina. 2024;60(10):1646. doi: 10.3390/medicina60101646
8. Jiang Y, Wang Y, Ma S, Qian L, Jing Y, Chen X, et al. Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis. Frontiers in Cardiovascular Medicine. 2025;11. doi: 10.3389/fcvm.2024.1415668
9. Abduljabbar MH. PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression. Pharmaceuticals. 2024;17(12):1581. doi: 10.3390/ph17121581
10. Nejabat M, Hadizadeh F, Almahmeed W, Sahebkar A. Effects of PCSK9 inhibitors on cancer, diabetes, and cardiovascular diseases. Drug Discovery Today. 2025;30(3):104316. doi: 10.1016/j.drudis.2025.104316
11. Chen H, Li X, Chen J, Zhao Y, Zhang W, Li H, et al. Lipid-lowering effect of evolocumab in hypertriglyceridemia-induced acute pancreatitis. European Journal of Pharmacology. 2025;1006:178148. doi: 10.1016/j.ejphar.2025.178148
12. Tanaka A, Oyama K, Yakushiji Y, Natsuaki M, Mizuno A, Saito Y, et al. Lipid Management for Secondary Prevention in Atherosclerotic Cardiovascular Disease: A Scoping Review and Scientific Report. Journal of Atherosclerosis and Thrombosis. 2025;. doi: 10.5551/jat.65908
13. Kroemer G, Maier AB, Cuervo AM, Gladyshev VN, Ferrucci L, Gorbunova V, et al. From geroscience to precision geromedicine: Understanding and managing aging. Cell. 2025;188(8):2043. doi: 10.1016/j.cell.2025.03.011